ClinicalTrials.gg
RecruitingNCT02000089CAPS5Updated Oct 22, 2026

The Cancer of the Pancreas Screening-5 CAPS5)Study

A Phase 3 interventional study of Secretin and MRI in Pancreas Cancer, Peutz-Jeghers Syndrome (PJS) and Gene Mutation, sponsored by Johns Hopkins University. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Johns Hopkins University · Phase 3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2014; still recruiting 12 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Pancreatic Neoplasms by Johns Hopkins University — 3 open to participants now, 3 under way, 1 of them phase 3. Pancreatic Neoplasms · Johns Hopkins University.

Started
2014
with 3 others
Phase 3
2 of 13
1 open now
Registered
7th of 13
by date

Among the 13 studies in Pancreatic Neoplasms by Johns Hopkins University, this one is one of 4 that started in 2014, is one of 2 in phase 3, and was the 7th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

3 of the 13 studies in Pancreatic Neoplasms by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Pancreatic Neoplasms by Johns Hopkins University, or all of them as a file.
02

Study summary

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Read the detailed description

The Sub Investigator at each site will be responsible for internal monitoring at their site. The site sub Investigator and study team will report any serious adverse events to Principal Investigator and annually report adverse events.

03

Conditions studied

  • Pancreas Cancer
  • Peutz-Jeghers Syndrome (PJS)
  • Gene Mutation
  • Germline Mutation Carrier
  • Lynch Syndrome

Keywords

  • familial pancreas cancer
  • (Peutz-Jeghers Syndrome) PJS
  • Breast cancer (BRCA) 2
  • Partner and Locator of BRCA2 (PALB2)
  • Familial Atypical Multiple Mole- Melanoma (FAMMM)
  • p16, CDKN2A
  • Breast Cancer (BRCA)1
  • (hereditary non-polyposis colorectal cancer or Lynch syndrome) HNPCC
  • Lynch Syndrome
  • hereditary pancreatitis
  • Protease Serine (PRSS)
  • Chymotrypsin C (CTRC)
  • Ataxia Telangiectasia Mutated(ATM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hereditary Pancreatitis or
  • Peutz-Jeghers Syndrome or
  • Strong family history of pancreas cancer on one side of the family tree or
  • Confirmed germline mutation carrier (BRCA2, FAMMM (CDKN2A/p16), PALB2, BRCA1, ATM, HNPCC, Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM) PRSS1, PRSS2, R122H, N291l, SPINK1, CFTR
  • Endoscopic evaluation of pancreas scheduled

Exclusion criteria

Exclusion Criteria:

  • Medical comorbidities or coagulopathy that contraindicate endoscopy
  • Prior surgery that prevent optimal endoscopic ultrasound such as partial or complete gastrectomy with Bilroth or Roux-en-Y anastomosis
  • Stricture or obstruction in the upper GI tract that does not allow passage of the echoendoscope
  • Poor performance status
  • Inability to provide
  • Pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
9,000 participants (estimated)

Study arms

  • Active comparator
    Familial pancreas cancer relatives

    High Risk Group 2 (familial pancreatic cancer relatives): 1. \> 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and 2. come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and 3. have a first-degree relationship with at least one of the relatives with pancreatic cancer. If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened

    Drug: Secretin · Diagnostic Test: MRI · Other: Tumor marker gene test with CA19-9

  • Active comparator
    Group 1 germline mutation carrier

    High Risk Group 3 (Group 1 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of \~10% or higher): a. \> 50 years old or 10 years younger than the age of the youngest relative affected, if pancreatic cancer is in family, and b. The Patient is a carrier of a confirmed BRCA2, ATM or PALB2 mutation, regardless of family history of pancreatic cancer. b.\> Individual is a carrier of a confirmed FAMMM (p16/CDKN2A) mutation, age 40 years or older, regardless of family history of pancreas cancer.

    Drug: Secretin · Diagnostic Test: MRI · Other: Tumor marker gene test with CA19-9

  • Active comparator
    Group 2 germline mutation carrier

    High Risk Group 4 (Group 2 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of \~5%): 1. \> 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and 2. The patient is a carrier of a confirmed BRCA1 or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is \> 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened.

    Drug: Secretin · Diagnostic Test: MRI · Other: Tumor marker gene test with CA19-9

  • Active comparator
    Hereditary pancreatitis

    High risk group 5 (hereditary pancreatitis) with confirmed gene mutations that predispose to chronic pancreatitis, such as PRSS1, PRSS2, CTRC) and age 50 years or older (these patients have an estimated lifetime risk for pancreatic cancer of 40%) or twenty-years since their first attack of pancreatitis, whichever age is younger.

    Drug: Secretin · Diagnostic Test: MRI · Other: Tumor marker gene test with CA19-9

  • Active comparator
    Peutz-Jeghers Syndrome

    1. At least 30 years old, and 2. at least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family history of Peutz-Jeghers syndrome), or, 3. known STK11 gene mutation carrier

    Drug: Secretin · Diagnostic Test: MRI · Other: Tumor marker gene test with CA19-9

  • Active comparator
    Negative control

    1. are undergoing routine EGD or Colonoscopy; or Endoscopic Ultrasound (EUS) and/or Endoscopic Retrograde Cholangiopancreatography (ERCP) for non-pancreatic indications as part of their standard medical care, and 2. have no clinical or radiologic suspicion of pancreatic disease (chronic pancreatitis or pancreatic cancer)

    Drug: Secretin

  • Active comparator
    Chronic Pancreatitis

    1. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven chronic pancreatitis as part of their standard medical care, and, 2. have no clinical or radiologic suspicion of pancreatic cancer

    Drug: Secretin

  • Active comparator
    Pancreas cancer

    a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)

    Drug: Secretin

  • Active comparator
    Pancreas cyst, IPMN evaluation

    are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer precursor, intraductal papillary mucinous neoplasm (based on clinical presentation and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct and/or pancreatic cystic lesion communicating with the pancreatic ductal system).

    Drug: Secretin

Interventions

  • inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.

    Also known as: ChiRhoStim

  • Diagnostic testMRI

    MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.

    Also known as: MRCP

  • OtherTumor marker gene test with CA19-9

    A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.

06

What researchers measure

Primary outcomes

  1. Evaluate pancreatic juice for early cancer markers.

    Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls.

    Time frame: 10 years

Secondary outcomes

  1. Compare pancreas juice with pancreas cyst fluid

    Aim #2: To compare the prevalence of pancreatic fluid mutations and circulating pancreatic epithelial cells among a prospective cohort of individuals with sporadic pancreatic cysts undergoing pancreatic surveillance.

    Time frame: 10 years

Other outcomes

  1. Time disease progression and prevalence

    Aim #3: To determine the prevalence of pancreatic lesions, pancreatic fluid mutations and circulating pancreatic epithelial cells among a large cohort of high-risk individuals undergoing pancreatic screening and surveillance of a new cohort in which screening is begun at age \>55.

    Time frame: 10 years

  2. Diagnostic performance of a tumor marker gene test for CA19-9 interpretation

    Aim #4 To evaluate the diagnostic performance of a tumor marker gene test to personalize the normal reference range of tumor markers such as CA19-9 for patients undergoing pancreatic surveillance.

    Time frame: 5 years

07

Study locations

9 of 9 sites recruiting
08

References and documents

Publications

  • Kumar S, Saumoy M, Oh A, Schneider Y, Brand RE, Chak A, Ginsberg GG, Kochman ML, Canto MI, Goggins MG, Hur C, Kastrinos F, Katona BW, Rustgi AK. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Pancreas. 2021 Jul 1;50(6):807-814. doi: 10.1097/MPA.0000000000001835. PubMed 34149034 ↗
  • Kohi S, Macgregor-Das A, Dbouk M, Yoshida T, Chuidian M, Abe T, Borges M, Lennon AM, Shin EJ, Canto MI, Goggins M. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2022 Feb;20(2):e196-e227. doi: 10.1016/j.cgh.2020.11.006. Epub 2020 Nov 5. PubMed 33161160 ↗
  • Abe T, Koi C, Kohi S, Song KB, Tamura K, Macgregor-Das A, Kitaoka N, Chuidian M, Ford M, Dbouk M, Borges M, He J, Burkhart R, Wolfgang CL, Klein AP, Eshleman JR, Hruban RH, Canto MI, Goggins M. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2020 May;18(5):1161-1169.e5. doi: 10.1016/j.cgh.2019.10.036. Epub 2019 Oct 30. PubMed 31676359 ↗
  • Canto MI, Kerdsirichairat T, Yeo CJ, Hruban RH, Shin EJ, Almario JA, Blackford A, Ford M, Klein AP, Javed AA, Lennon AM, Zaheer A, Kamel IR, Fishman EK, Burkhart R, He J, Makary M, Weiss MJ, Schulick RD, Goggins MG, Wolfgang CL. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. J Gastrointest Surg. 2020 May;24(5):1101-1110. doi: 10.1007/s11605-019-04230-z. Epub 2019 Jun 13. PubMed 31197699 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2014 (actual). Primary completion is estimated for Dec 2028, 179 months after the start.

Of 46 non-industry phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 79. This study's planned 179 months is above that.

Counting every sponsor, half of 84 studies reached it within 60 months; a quarter within 36 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2013
First posted
Dec 3, 2013
StartActual
Jan 6, 2014
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2029
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • Dana Farber Cancer Center, Harvard University · Boston, United StatesContact S•••@dfci.harvard.edu · •••4788→I•••@dfci.harvard.edu · •••7938Contact none listed→•••4788
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Dana Farber Cancer Center, Harvard University · Boston, United StatesContact S•••@dfci.harvard.edu · •••4788→I•••@dfci.harvard.edu · •••7938Contact none listed→•••4788
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02000089
Collaborators
National Cancer Institute (NCI), National Institutes of Health (NIH), American Association for Cancer Research
Responsible party
Sponsor
First posted
Dec 3, 2013
Start date
Jan 6, 2014
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 22, 2026

Study contacts

Hilary Cosby, RN
Contact
hcosby1@jhmi.edu
Michael Goggins, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion